Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Is percutaneous nephrolithotomy in thrombocytosis patient safe? A retrospective case series analysis.

Created on 22 Aug 2025

Authors

Bimalesh Purkait, Himadri Pathak, Kaushik Sarkar, Argha Mondal, Sachin Kumar Karnwal, Anjan Kumar Das

Published in

Urology annals. Volume 17. Issue 3. Pages 201-205. Epub Jul 18, 2025.

Abstract

Percutaneous nephrolithotomy (PCNL) is the gold standard for large and complex renal stone despite other available modalities. PCNL techniques have been evolved with many modifications and innovation in the recent decade. It can be safely performed in elderly patient and children with highest stone-free rate (SFR) among all other modalities. However, as PCNL is a blind procedure, chance of bleeding is very high than other surgical modalities. If patient already had, hematological problem, then perioperative risk of bleeding increased significantly. We are presenting few cases of PCNL in thrombocytosis child and young adult. This is a retrospective analysis of four renal stone patients from 2017 to 2024. Surgical outcomes such as SFR and complications were analyzed and discussed. There were no major perioperative bleeding problems in our study. Mild-to-moderate thrombocytosis does not pose extra risk to bleeding. However, hematology opinion and informed decision are needed for risk stratification before performing PCNL.

PMID:
40843408
Bibliographic data and abstract were imported from PubMed on 22 Aug 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 50
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement